Ossianix Inc logo

Ossianix Inc

Ossianix, is a privately held pre clinical stage company developing biotherapeutic using highly versatile single domain VNAR antibody from the shark. Current programs focus on autoimmunity, neurodegereration, ALS, pain and botulism.

The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.ossianix.co.uk
Founded2011
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Stevenage Bioscience Catalyst, Gunnels Wood Rd, Stevenage, Hertfordshire, SG12FX
Stevenage
United Kingdom
Email
Contact Number
+44 1438906821

In 2012 Ossianix, established a collaboration with Lundbeck focusing on two proprietary neurodegeneration targets and have delivered several versions of the antibodies for these targets.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/ossianix” connections=”true” suffix=””]

Ossianiss VNAR drug discovery platform utilizes the versatile single domain shark VNAR scaffold to engineer unique differentiated products in a variety of formats including monospecific and bispecifics antibodies, which can cross blood brain barrier to target specific cells and tissues such as the brain and peripheral nerve via the neuromuscular junction.

Jan 2017, Ossianix receives undisclosed milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology.